Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Haematological malignancies: Latest advances from ASH 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.03.20
Views: 131

Dr Eloísa Riva - Hospital de Clínicas, Montevideo, Uruguay

Dr Eloísa Riva speaks to ecancer at the ASH 2019 meeting in Orlando about the main highlights from the meeting.

She begins by highlighting the emergence of new tools for the detection of monoclonal proteins, including the use of mass spectrometry.  

Dr Riva also discusses the use of quadruple therapy, which has shown to increase the overall response rate and depth of response compared to triple therapy.

She also explains the latest developments in triple-refractory disease, including the STOMP trial and the TOURMALINE-AL1 for patients with relapsed/refractory primary systemic AL amyloidosis.

Dr Riva concludes by stating the importance of this meeting for Latin American research groups, as it provides them with the opportunity for collaboration, education and training. 


Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation